References
- 1. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016;37:3232-3245. doi: 10.1093/eurheartj/ehw334.10.1093/eurheartj/ehw334
- 2. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119-177. doi: 10.1093/eurheartj/ehx393.10.1093/eurheartj/ehx393
- 3. Hartley A, Marshall DC, Salciccioli JD, Sikkel MB, Maruthappu M, Shalhoub J. Trends in Mortality From Ischemic Heart Disease and Cerebrovascular Disease in Europe: 1980 to 2009. Circulation. 2016;133:1916-1926. doi: 10.1161/circulationaha.115.018931.10.1161/CIRCULATIONAHA.115.018931
- 4. Puymirat E, Simon T, Steg PG, et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA. 2012;308:998-1006. doi: 10.1001/2012. jama.11348.10.1001/2012.jama.11348
- 5. Resnic FS, Wainstein M, Lee MK, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J. 2003;145:42-46. doi: 10.1067/mhj.2003.36.10.1067/mhj.2003.36
- 6. Hamada S, Nishiue T, Nakamura S, et al. TIMI frame count immediately after primary coronary angioplasty as a predictor of functional recovery in patients with TIMI 3 reperfused acute myocardial infarction. J Am Coll Cardiol. 2001;38:666-671. doi: 10.1016/s0735-1097(01)01424-3.10.1016/S0735-1097(01)01424-3
- 7. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879-888 doi: 10.1161/01.cir.93.5.879.10.1161/01.CIR.93.5.879
- 8. Angeja BG, Gunda M, Murphy SA, et al. TIMI myocardial perfusion grade and ST segment resolution: association with infarct size as assessed by single photon emission computed tomography imaging. Circulation. 2002;105:282-285. doi: 10.1161/hc0302.103588.10.1161/hc0302.10358811804979
- 9. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138:e618-e651. doi: 10.1161/cir.0000000000000617.10.1161/CIR.000000000000061730571511
- 10. van ‘t Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation. 1998;97:2302-2306. doi: 10.1161/01.cir.97.23.2302.10.1161/01.CIR.97.23.2302
- 11. Fabris E, van ‘t Hof A, Hamm CW, et al. Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial. Eur Heart J Acute Cardiovasc Care. 2019;8:208-217. doi: 10.1177/2048872617727722.10.1177/204887261772772228841028
- 12. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002;105:1909-1913. doi: 10.1161/01.cir.0000014683.52177.b5.10.1161/01.CIR.0000014683.52177.B5
- 13. Winter JL, Lindefjeld DS, Veas N, et al. Angiographic and electrocardiographic parameters of myocardial reperfusion in angioplasty of patients with ST elevation acute myocardial infarction loaded with ticagrelor or clopidogrel (MICAMITICLO trial). Cardiovasc Revasc Med. 2014;15:284-288. doi: 10.1016/j.carrev.2014.07.001.10.1016/j.carrev.2014.07.001
- 14. Hoffmann R, Haager P, Arning J, et al. Usefulness of myocardial blush grade early and late after primary coronary angioplasty for acute myocardial infarction in predicting left ventricular function. Am J Cardiol. 2003;92:1015-1019. doi: 10.1016/j. amjcard.2003.07.001.10.1016/j.amjcard.2003.07.001
- 15. Haager PK, Christott P, Heussen N, Lepper W, Hanrath P, Hoffmann R. Prediction of clinical outcome after mechanical revascularization in acute myocardial infarction by markers of myocardial reperfusion. J Am Coll Cardiol. 2003;41:532-538. doi: 10.1016/s0735-1097(02)02870-x.10.1016/S0735-1097(02)02870-X
- 16. Kaya MG, Arslan F, Abaci A, van der Heijden G, Timurkaynak T, Cengel A. Myocardial blush grade: a predictor for major adverse cardiac events after primary PTCA with stent implantation for acute myocardial infarction. Acta Cardiol. 2007;62:445-451. doi: 10.2143/ac.62.5.2023406.10.2143/AC.62.5.202340617982964
- 17. Brener SJ, Dizon JM, Mehran R, et al. Complementary prognostic utility of myocardial blush grade and ST-segment resolution after primary percutaneous coronary intervention: analysis from the HORIZONS-AMI trial. Am Heart J. 2013;166:676-683. doi: 10.1016/j.ahj.2013.07.025.10.1016/j.ahj.2013.07.02524093847
- 18. Di Vito L, Versaci F, Limbruno U, et al. Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction. J Cardiovasc Med (Hagerstown). 2016;17:701-706. doi: 10.2459/jcm.0000000000000392.10.2459/JCM.000000000000039227467458
- 19. Savi P, Zachayus JL, Delesque-Touchard N, et al. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A. 2006;103:11069-11074. doi: 10.1073/pnas.0510446103.10.1073/pnas.0510446103163515316835302
- 20. Algaier I, Jakubowski JA, Asai F, von Kugelgen I. Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor. J Thromb Haemost. 2008;6:1908-1914. doi: 10.1111/j.1538-7836.2008.03136.x.10.1111/j.1538-7836.2008.03136.x18752581
- 21. Cattaneo M. New P2Y(12) inhibitors. Circulation. 2010;121:171-179. doi: 10.1161/circulationaha.109.853069.10.1161/CIRCULATIONAHA.109.85306920048234
- 22. Vang JJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7:1556-1165. doi: 10.1111/j.1538-7836.2009.03527.x.10.1111/j.1538-7836.2009.03527.x19552634
- 23. Jeon HS, Kim MJ, Choi HY, et al. Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. Clin Ther. 2015;37:563-573. doi: 10.1016/j.clinthera.2015.01.010.10.1016/j.clinthera.2015.01.01025697420
- 24. Hagihara K, Kazui M, Kurihara A, et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos. 2009;37:2145-2152. doi: 10.1124/dmd.109.028498.10.1124/dmd.109.02849819704027
- 25. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013;61:1601-1606. doi: 10.1016/j.jacc.2013.01.024.10.1016/j.jacc.2013.01.02423500251